AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease

Crohn’s disease manifests as inflammation within the gastrointestinal tract, and causes continuous diarrhea and abdominal pain. Credit: Darko Djurin from Pixabay